FLT1

ENSG00000102755
Target class
Kinase
Chromosome
13
Approved drugs
12
Clinical candidates (approved and in development)
47

Approved drugs
12
Clinical candidates (approved and in development)
47

Chemical probe available
Yes

Other names
  • VEGFR1
Target name
FLT1
Gene name
Fms related receptor tyrosine kinase 1
Gene symbol
FLT1
Previous gene symbols
  • FLT
Protein name
Vascular endothelial growth factor receptor 1 (VEGFR-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 1) (FLT-1) (Tyrosine-protein kinase FRT) (Tyrosine-protein kinase receptor FLT) (FLT) (Vascular permeability factor receptor)

Gene biotype
Protein coding
Gene family
Receptor tyrosine kinases|V-set domain containing|I-set domain containing
Target class
Kinase
Target type
Human gene

Tissues expressed in
53
Protein localisation evidence grade
Supported
Highest tissue expression
54.17
Tissue specificity (Gini)
0.359
Tissue specificity (tau)
0.803

KEGG gene identifiers
  • hsa:2321
Protein interaction confidence
0.838105
Protein interaction partners
86

  • R-HSA-194306
  • R-HSA-195399

End position
28495145
Start position
28300346
Chromosome
13
Strand
Reverse

Ensembl gene ID
ENSG00000102755
HGNC ID
HGNC:3763
www.genenames.org
NCBI Gene ID
2321
UniProt ID
P17948

  • [Isoform 1]: Cell membrane
  • Single-pass type I membrane protein. Endosome. Note=Autophosphorylation promotes ubiquitination and endocytosis.
  • SUBCELLULAR LOCATION: [Isoform 2]: Secreted .
  • SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
  • SUBCELLULAR LOCATION: [Isoform 4]: Secreted.
  • SUBCELLULAR LOCATION: [Isoform 5]: Cytoplasm .
  • SUBCELLULAR LOCATION: [Isoform 6]: Cytoplasm .
  • SUBCELLULAR LOCATION: [Isoform 7]: Cytoplasm .
  • Actin filaments
  • Cytosol
  • Plasma membrane

Publication evidence

Tissue specificity (tau)
0.803083
Expression inequality (Gini)
0.358525

Expression in transcripts per million

Thyroid
54.17
Adipose - Visceral (Omentum)
35.69
Adipose - Subcutaneous
28.61
Lung
25.39
Breast - Mammary Tissue
25.34

Expression in transcripts per million

  • Thyroid54.17
  • Adipose - Visceral (Omentum)35.69
  • Adipose - Subcutaneous28.61
  • Lung25.39
  • Breast - Mammary Tissue25.34
  • Uterus21.51
  • Cervix - Endocervix16.81
  • Kidney - Cortex15.69
  • Cervix - Ectocervix15.59
  • Nerve - Tibial14.61
  • Brain - Spinal cord (cervical c-1)14.53
  • Brain - Substantia nigra14.43
  • Heart - Atrial Appendage14.16
  • Fallopian Tube13.68
  • Prostate13.62
  • Artery - Coronary13.28
  • Heart - Left Ventricle12.6
  • Kidney - Medulla11.81
  • Brain - Caudate (basal ganglia)11
  • Brain - Frontal Cortex (BA9)10.38
  • Brain - Cerebellar Hemisphere10.33
  • Brain - Hippocampus10.29
  • Brain - Hypothalamus10.21
  • Esophagus - Muscularis10.14
  • Brain - Putamen (basal ganglia)10.05

And 29 more, listed on the interactive page.

  • impaired healing

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • brain natriuretic peptide increase

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • metabolic/endocrine
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • heart disease

    Studies

    • preclinical: Highly important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Crucial in angiogenesis and the heart’s response to pressure overload; antihypertensive effects

    Biological samples

    • cardiovascular system
    PubMed 21283106
    pubmed.ncbi.nlm.nih.gov

  • Increased, Developmental Defects

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • cell-based
    Evidence source
    aopwiki.org

  • hyponatraemia

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • metabolism
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • Haemorrhage

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • CV
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • hypertension

    Effects

    • Inhibition/Decrease/Downregulation

    Studies

    • clinical

    Biological samples

    • CV
    PubMed 38773351
    pubmed.ncbi.nlm.nih.gov

  • regulation of catalytic activity

    • biochemical: NVS_ENZ_hVEGFR1, is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
    • biochemical: NVS_ENZ_hVEGFR1, is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.

    Biological samples

    • cell-free
    Evidence source
    www.epa.gov

Related records

Trials (3,458)

Drugs (52)